NuVasive on Nov. 9 posted third quarter net sales of $295.3 million.
Four things to know:
1. Third quarter revenue increased 9 percent year-over-year. The uptick was driven by increased adoption of new products, higher procedure volume in the U.S. and strong international sales.
2. NuVasive saw a net loss of $2 million, compared to a net loss of $21.6 million in the third quarter of 2021.
3. The company lowered its 2022 guidance range for net sales from 6 percent to eight percent, to 5.5 percent to 6.5 percent in net sales growth.
4. CEO Chris Barry said, "The strategic investments we've made in product and technology innovation are delivering continued above-market growth — as demonstrated by double-digit growth in net sales on a constant currency basis. Despite the challenging macro environment, we continue to execute as evidenced by our top- and bottom-line performance in the quarter."